InvestorsHub Logo
Followers 230
Posts 43009
Boards Moderated 1
Alias Born 03/15/2011

Re: None

Wednesday, 04/29/2020 4:19:42 PM

Wednesday, April 29, 2020 4:19:42 PM

Post# of 8936
$CAPR DD Summary

Within 2 weeks there is a 12 month DMD trial results due.

Major success and approvable endpoints on 6 month DMD trial

http://irdirect.net/prviewer/release/id/4287978

There is only one major competitor in the DMD space - Sarepta’s Exondys 51 which only targets 14% of DMD patients.

https://en.m.wikipedia.org/wiki/Eteplirsen

This one targets 100% of non ambulant DMD patients which is 10,000 in USA at $200k annual cost of treatment = $2B annual revenues

12.5 million confirmed OS
1.5 million owned by management and institutions
= total float is ~11 million shares

$20 per share = $250 Million market cap

————-

Watch this DD:



Furthermore Capricor’s exosome compassionate use emergency treatment got 100% success rate and an FDA approval and nod for a further 20 patient trial - to be funded with non dilutive capital.

http://irdirect.net/prviewer/release/id/4306152

P1 and human trials might soon begin on the covid 19 vaccine seeing success with exosomes and FDA approval.

Huge opportunity

EUCALYPTUS

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CAPR News